What are the indications, dosing regimens, contraindications, and adverse effects of metoclopramide?

Metoclopramide: Clinical Overview

Indications

Metoclopramide is FDA-approved specifically for diabetic gastroparesis and is the only medication with this approval for gastroparesis treatment. 1

Primary Indications:

• Diabetic gastroparesis (FDA-approved) 1
• Chemotherapy-induced nausea and vomiting, particularly with cisplatin at high doses (1-2 mg/kg per dose) 2, 3
• Radiation-induced nausea and vomiting for low-risk radiation therapy (brain, head and neck, thorax, pelvis) 2
• Facilitating small bowel intubation and radiographic procedures 4

Off-Label Uses:

• Medically refractory gastroparesis (idiopathic and diabetic) 1
• Gastroesophageal reflux disease (severe cases) 5
• Acute migraine attacks - metoclopramide 10 mg IV is effective with level B recommendation (should offer) 6
• Postoperative nausea and vomiting 5

---

Dosing Regimens

For Gastroparesis:

• 5-20 mg orally three to four times daily 1
• Treatment duration should be limited to 4-12 weeks for oral preparations 5

For Chemotherapy-Induced Nausea/Vomiting:

• High-dose protocol: 2 mg/kg IV for 5 doses over 9 hours, beginning 30 minutes before cisplatin (≥120 mg/m²) 3
• Intermediate-dose: 1 mg/kg for 6 doses (for cisplatin ≤50 mg/m²) 3
• Short-course: 2 mg/kg for 3 doses (outpatient setting) 3

For Radiation-Induced Nausea/Vomiting:

• 5-20 mg oral or IV as breakthrough therapy for low-risk radiation 2
• Titrate up to maximum of 16 mg daily 2

For Acute Migraine:

• 10 mg IV is the most frequently used and effective dose 6, 7

Route Considerations:

• Intravenous route is most commonly used and shows significant positive results 7
• Parenteral use should be limited to 1-2 days 5

---

Contraindications

Metoclopramide is absolutely contraindicated in several critical situations: 8

Absolute Contraindications:

• Gastrointestinal hemorrhage, mechanical obstruction, or perforation - stimulation of GI motility is dangerous 8
• Pheochromocytoma - may cause hypertensive crisis due to catecholamine release from tumor (controlled with phentolamine) 8
• Known hypersensitivity or intolerance to metoclopramide 8
• Epilepsy or concurrent use of drugs causing extrapyramidal reactions - increases frequency and severity of seizures and extrapyramidal symptoms 8

Relative Contraindications/Cautions:

• Concomitant use with MAO inhibitors, tricyclic antidepressants, or sympathomimetic amines 4
• Possible AV block risk - cardiovascular monitoring needed 8

---

Adverse Effects

Common CNS Effects (dose and duration-dependent):

• Drowsiness (approximately 70% in cancer chemotherapy patients at 1-2 mg/kg doses) 8
• Restlessness, fatigue, and lassitude 8, 5
• Insomnia, headache, confusion, dizziness 8
• Mental depression with suicidal ideation 8

Extrapyramidal Reactions (EPS):

Acute dystonic reactions are the most common EPS type: 8

• Occur in approximately 0.2% (1 in 500) of patients on 30-40 mg daily 8
• 25% or higher incidence in pediatric patients and adults <30 years old without prophylactic diphenhydramine 8
• 2% incidence in patients >30-35 years at chemotherapy doses 8

Symptoms include:

• Involuntary limb movements, facial grimacing, torticollis, oculogyric crisis 8
• Rhythmic tongue protrusion, bulbar speech, trismus, opisthotonus 8
• Rarely: stridor and dyspnea from laryngospasm 8
• Readily reversed by diphenhydramine 8

Motor restlessness (akathisia):

• Anxiety, agitation, jitteriness, insomnia, inability to sit still, pacing, foot tapping 8
• May disappear spontaneously or with dose reduction 8

Parkinsonian-like symptoms:

• Bradykinesia, tremor, cogwheel rigidity, mask-like facies 8

Tardive Dyskinesia:

The actual risk is far lower than previously estimated: 9

• True risk: 0.1% per 1000 patient-years (not the 1-10% suggested in older guidelines) 9
• Characterized by involuntary movements of tongue, face, mouth, jaw, and sometimes trunk/extremities 8
• Movements may be choreoathetotic 8

High-risk groups for tardive dyskinesia: 9

• Elderly females
• Diabetics
• Patients with liver or kidney failure
• Concomitant antipsychotic drug therapy

Time to Onset of Neurological ADRs:

Most neurological adverse reactions occur rapidly: 10

• Median time to onset: 1 day 10
• Majority occur within first 5 days of treatment 10
• Time to onset increases with age 10
• Children have highest reporting ratios (PRR = 4.24 for girls, 4.60 for boys) 10

Neuroleptic Malignant Syndrome (NMS):

• Rare but potentially fatal 8
• Symptom complex: hyperthermia, muscular rigidity, altered consciousness, autonomic instability 8

Endocrine Disturbances:

• Galactorrhea, amenorrhea, gynecomastia, impotence secondary to hyperprolactinemia 8, 11
• Fluid retention from transient aldosterone elevation 8

Cardiovascular Effects:

• Hypotension, hypertension, supraventricular tachycardia, bradycardia 8
• Fluid retention, acute congestive heart failure 8
• Possible AV block 8

Other Adverse Effects:

• Gastrointestinal: Nausea, diarrhea 8
• Hematologic: Rare neutropenia, leukopenia, agranulocytosis; methemoglobinemia (especially in neonates with overdose) 8
• Hepatic: Rare hepatotoxicity when combined with other hepatotoxic drugs 8
• Renal: Urinary frequency and incontinence 8
• Allergic: Rash, urticaria, bronchospasm (especially in asthmatics); rarely angioedema 8

---

Clinical Pearls and Risk Mitigation

Duration Limitations:

Regulatory authorities recommend limiting treatment duration due to tardive dyskinesia risk, though actual risk is lower than historically stated: 9

• Oral therapy: 4-12 weeks maximum 5
• Parenteral therapy: 1-2 days maximum 5

Monitoring Strategy:

Patients must be carefully monitored for neurological ADRs during the first 5 days of treatment, as this is when most reactions occur. 10

Special Populations Requiring Extra Caution:

• Elderly females with diabetes - highest risk group 9
• Patients <30 years old - consider prophylactic diphenhydramine for high-dose regimens 8
• Patients with renal or hepatic impairment - increased drug exposure and risk 9
• Patients on antipsychotics - lower threshold for neurological complications 9

Mechanism of Action Context:

Metoclopramide works as a dopamine receptor antagonist with 5-HT3 receptor antagonist and 5-HT4 receptor agonist activity 9. It enhances gastric emptying by augmenting esophageal peristalsis, gastric antral contractions, and small intestine transit time while increasing lower esophageal and pyloric sphincter pressures 4. Its antiemetic effect results from action on the chemoreceptor trigger zone 11, 5.